Long-lasting response to third-line chemotherapy in metastatic pancreatic cancer. Issue 3 (4th May 2020)

• Record Type: Journal Article
• Authors: Tavares, Alda; Mesquita, Alexandra
• Is Part Of: Porto biomedical journal. Volume 5:Issue 3(2020)
• Page Start: e65
• Publication Date: 2020-05-04
• Subjects: chemotherapy -- long term -- metastasis -- pancreatic neoplasms; 610.28
• DOI: 10.1097/j.pbj.0000000000000065
• Languages: English
• ISSNs: 2444-8664

Abstract

Abstract : Abstract: At diagnosis, approximately 50% of cases of adenocarcinoma of the pancreas are metastasized and 5-year survival is only 2.9%. We reported a case of a 63-year-old woman with pancreatic adenocarcinoma with multiple hepatic and intra-abdominal metastases that progressed on 2 lines of chemotherapy. She has been under treatment with third-line chemotherapy for 19 months with stable disease and excellent performance status. She has an overall survival of 29 months. There are just a few cases of metastatic disease with long survival described in the literature. The functional status and the good tolerance to treatment may be determinants of prognosis.